DE122005000021I1 - Pharmazeutische formulierung - Google Patents

Pharmazeutische formulierung

Info

Publication number
DE122005000021I1
DE122005000021I1 DE200512000021 DE122005000021C DE122005000021I1 DE 122005000021 I1 DE122005000021 I1 DE 122005000021I1 DE 200512000021 DE200512000021 DE 200512000021 DE 122005000021 C DE122005000021 C DE 122005000021C DE 122005000021 I1 DE122005000021 I1 DE 122005000021I1
Authority
DE
Germany
Prior art keywords
pct
date
pharmaceutical formulation
sec
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE200512000021
Other languages
English (en)
Inventor
Christer Nystroem
Lennart Paalzow
Sten-Magnus Aquilonius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neopharma AB
Original Assignee
Neopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma AB filed Critical Neopharma AB
Publication of DE122005000021I1 publication Critical patent/DE122005000021I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE200512000021 1992-11-30 1993-11-29 Pharmazeutische formulierung Pending DE122005000021I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (1)

Publication Number Publication Date
DE122005000021I1 true DE122005000021I1 (de) 2006-02-23

Family

ID=20387973

Family Applications (2)

Application Number Title Priority Date Filing Date
DE200512000021 Pending DE122005000021I1 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung
DE69326350.4T Expired - Lifetime DE69326350T3 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69326350.4T Expired - Lifetime DE69326350T3 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung

Country Status (15)

Country Link
US (1) US5635213A (de)
EP (1) EP0670713B3 (de)
JP (1) JP3661703B2 (de)
AT (1) ATE184191T3 (de)
AU (1) AU688290B2 (de)
CA (1) CA2150464C (de)
DE (2) DE122005000021I1 (de)
DK (1) DK0670713T3 (de)
ES (1) ES2137350T7 (de)
FR (1) FR04C0024I2 (de)
GR (1) GR3031988T3 (de)
NL (1) NL300169I1 (de)
NZ (1) NZ258276A (de)
SE (1) SE9203594D0 (de)
WO (1) WO1994012153A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP2272514A1 (de) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Verwendung von niedrigdosiertem Pipamperon und einem zweiten Wirkstoff zur Behandlung von neurodegenerativen Erkrankungen
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
MX2008015339A (es) * 2006-05-31 2008-12-16 Solvay Pharm Gmbh Administracion intestinal a largo plazo durante 24 horas de levodopa/carbidopa.
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2170283B1 (de) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Bildung eines stabilen submikron-peptids oder von proteinteilchen durch dünnfilm-gefrieren
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10335540B2 (en) 2012-04-17 2019-07-02 Micrel Medical Devices S.A. Pharmaceutical blend infusion thereof and Parkinson's disease monitoring system
WO2016036308A1 (en) 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AR102389A1 (es) 2014-10-21 2017-02-22 Abbvie Inc Profármacos de carbidopa y l-dopa y métodos de uso de los mismos, kit
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018017850A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and carbidopa intestinal gel and methods of use
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
AU2019237857A1 (en) 2018-03-23 2020-10-08 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
DE69326350T2 (de) 2000-01-27
FR04C0024I1 (de) 2004-03-12
ES2137350T3 (es) 1999-12-16
ATE184191T3 (de) 1999-09-15
DE69326350T3 (de) 2018-01-11
AU5583694A (en) 1994-06-22
JP3661703B2 (ja) 2005-06-22
NZ258276A (en) 1996-09-25
DK0670713T3 (da) 2000-03-20
FR04C0024I2 (de) 2010-12-31
CA2150464C (en) 2002-02-05
CA2150464A1 (en) 1994-06-09
ES2137350T7 (es) 2017-11-13
NL300169I1 (nl) 2005-03-01
US5635213A (en) 1997-06-03
EP0670713A1 (de) 1995-09-13
DE69326350D1 (de) 1999-10-14
EP0670713B1 (de) 1999-09-08
WO1994012153A1 (en) 1994-06-09
JPH08504764A (ja) 1996-05-21
SE9203594D0 (sv) 1992-11-30
GR3031988T3 (en) 2000-03-31
EP0670713B3 (de) 2016-10-05
AU688290B2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
DE69326350D1 (de) Pharmazeutische formulierung
ES2115945T3 (es) Preparaciones topicas cosmeticas y medicinales.
DE69305328T2 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ES2052016T3 (es) Composicion emulsionada.
ATE333867T1 (de) Emulgierte arzneistoffabgabesysteme
TW347339B (en) Oral delivery of discrete units
FI970788A (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
ATE241990T1 (de) 3-beta-hydroxylierte natürliche steroidderivate enthaltende arzneimittelzusammensetzungen und ihre verwendung
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
MY101791A (en) New benzimidazole derivatives
ATE162725T1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
ES2091012T3 (es) Preparacion y utilizacion de nuevos sistemas coloidales dispersables a base de ciclodextrina, en forma de nanoesferas.
DE69106501T2 (de) Osmotisches dosiersystem zur verabreichung von flüssigen arzneimitteln.
DE69414840T2 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
MX9307256A (es) Dispositivo de administracion que tiene excipientes capsulados.
ES2125679T3 (es) Sistema transdermico de administracion simultanea de varios principios activos.
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
IE873125L (en) Benzimidazole derivatives
TR200002683T1 (tr) Bir protein ilaç veya antijen içeren lipofilik mikropartiküller ve bunları içeren formülasyon
MY102411A (en) Nasal solutions
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
DK0804152T3 (da) Lactulose-pastiller
DE59406568D1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel